Funding biotech: Do we need a superfund?
- Biotech
- •
- Pharma
- •
- Investment
Last year Mark Kessel called for the establishment of a biotech superfund funded by pharma, outlining the capital crisis faced by the biopharma industry and its negative impact on innovative therapies. He wrote that a superfund, modeled after the successful SEMATECH superfund, is a viable tool to address the need to fund innovation. This panel discusses the capital crisis, its effect on innovation and the possibility of creating a superfund.
Full stream
Moderator: Brady Huggett – Nature Publishing Group
- Frances K. Heller – Bristol-Myers Squibb
- Martin Mackay – AstraZeneca
- Harri V. Taranto – Symphony Capital
- Mary Woolley – Research!America
- Daphne Zohar – PureTech Ventures
